Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay

Yoshida, Shiomi; Suzuki, Katsuhiro; Iwamoto, Tomotada; Tsuyuguchi, Kazunari; Tomita, Motohisa; Okada, Masaji; Sakatani, Mitsunori

doi:10.1007/s10156-010-0057-5

Cited by 20 publications

(20 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Certain mutations in the RIF resistance determining region (RRDR) of the rpoB gene of MTBC appear to confer cross-resistance to both RIF and RFB (11 – 21). The mutations S531L, H526Y and H526D are most common and are found in isolates from a majority of MDR-TB patients.…”

Section: Introductionmentioning

confidence: 99%

Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex

Berrada

Lin

Rodwell

et al. 2016

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

Cross-resistance in rifamycins has been observed in rifampin (RIF)-resistant Mycobacterium tuberculosis complex isolates; some rpoB mutations do not confer broad in vitro rifamycin resistance. We examined 164 isolates, of which 102 were RIF-resistant, for differential resistance between RIF and rifabutin (RFB). A total of 42 unique single mutations or combinations of mutations were detected. The number of unique mutations identified exceeded that reported in any previous study. RFB and RIF MICs up to 8 µg/ml by MGIT 960 were studied; the cut-off values for susceptibility to RIF and RFB were 1 µg/ml and 0.5 µg/ml, respectively. We identified 31 isolates resistant to RIF but susceptible to RFB with the mutations, D516V, D516F, 518 deletion, S522L, H526A, H526C, H526G, H526L and two dual mutations (S522L+K527R and H526S+K527R). Clinical investigations using RFB to treat MDR TB cases harboring those mutations are recommended.

show abstract

Section: Introductionmentioning

confidence: 99%

Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex

Berrada

Lin

Rodwell

et al. 2016

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

show abstract

“…Although high-level cross-resistance between the two rifamycins is reported, some studies have shown RFB susceptibility in RIF-resistant strains of M. tuberculosis in association with specific rpoB mutations (Cavusoglu et al, 2004; Yoshida et al, 2010; Jamieson et al, 2014; ElMaraachli et al, 2015). Thus, it has been argued that knowing the type of rpoB mutation may have clinical implications for guiding rifamycin-based therapeutic regimens (Sirgel et al, 2013; Berrada et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Correlation of rpoB Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS Endemic Setting, South Africa

Rukasha

Said

Omar³

et al. 2016

Front. Microbiol.

View full text Add to dashboard Cite

Treatment of tuberculosis (TB) and HIV co-infections is often complicated by drug-to-drug interactions between anti-mycobacterial and anti-retroviral agents. Rifabutin (RFB) is an alternative to rifampin (RIF) for TB regimens and is recommended for HIV patients concurrently receiving protease inhibitors because of reduced induction of CYP3A4. This study sought to determine the proportion of RFB susceptible isolates among RIF-resistant strains in a high HIV prevalence setting in South Africa. In addition, the study explored the association between rpoB mutations and minimum inhibitory concentrations (MIC) of RIF and RFB. A total of 189 multidrug resistant (MDR) Mycobacterium tuberculosis isolates from the Centre for Tuberculosis repository were analyzed. The MICs were determined using a MYCOTB Sensititre plate method and the rpoB gene was sequenced. Of the 189 MDR isolates, 138 (73%) showed resistance to both RIF and RFB, while 51 (27%) isolates were resistant to RIF but retained susceptibility to RFB. The S531L was the most frequent rpoB point mutation in 105/189 (56%) isolates, followed by H526Y in 27/189 (14%) isolates. Resistance to both RIF and RFB was found predominantly in association with mutations S531L (91/105, 87%), H526Y (20/27, 74%), and H526D (15/19, 79%), while D516V (15/17, 88%), and L533P (3/4, 75%) were found in RIF-resistant, RFB-susceptible isolates. This study has shown that up to 27% of MDR-TB patients in South Africa may benefit from a treatment regimen that includes RFB.

show abstract

“…The GenoType MTBDRplus assay has been successfully applied to detection of culture samples since 2007 and clinical specimens since 2010 in Taiwan. Moreover, D516V mutation of the rpoB gene has been confirmed to confer resistance specifically to RIF in the commercial INNO-LiPA Rif assay (11,13). The GenoType MTBDRplus assay also has a probe targeting D516V that might be used for identification of RFB susceptibility.…”

mentioning

confidence: 99%

Molecular Detection of Rifabutin-Susceptible Mycobacterium tuberculosis

Chen¹,

Huang³

et al. 2012

J Clin Microbiol

View full text Add to dashboard Cite

Rapid assays are still needed to detect rifabutin (RFB) susceptibility for proper tuberculosis treatment. To assess the use of the GenoType MTBDRplus assay and subsequent rpoB gene sequencing on detection of RFB susceptibility, we analyzed 800 multidrug-resistant Mycobacterium tuberculosis isolates, and 13% (104/800) were RFB susceptible. Of the 104 RFB-susceptible isolates, 71 (68.3%) isolates were rapidly identified using two molecular assays, while the remaining isolates could be determined using conventional drug-susceptibility testing according to the clinician's decision.

show abstract

Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay

Cited by 20 publications

References 14 publications

Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex

Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex

Correlation of rpoB Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS Endemic Setting, South Africa

Molecular Detection of Rifabutin-Susceptible Mycobacterium tuberculosis

Contact Info

Product

Resources

About